Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Relying on a single strand of hair, LinusBio is launching its diagnostic aid for autism spectrum disorder—with a test ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...